Treatment of Depression with Vortioxetine in a Patient with Comorbid Major Depressive Disorder and Restless Legs Syndrome: A Case Report

Noro Psikiyatr Ars. 2022 Apr 28;59(2):164-166. doi: 10.29399/npa.27827. eCollection 2022.

Abstract

Many case reports have shown that the use of antidepressants can lead to restless legs syndrome (RLS). Vortioxetine is a new generation antidepressant with a multimodal mechanism of action on serotonin receptors. In this case report, partial improvement in RLS symptoms after treatment with vortioxetine in a patient with a co-diagnosis of major depressive disorder and restless legs syndrome will be discussed. A 59-year-old female patient was admitted to the psychiatry outpatient clinic due to depressive complaints for three months. In the control examination, it was learned that the patient had complaints of RLS that had been going on for about 20 years. RLS symptoms were increased with selective serotonin reuptake inhibitors (SSRI) used by the patient. In the follow-up examination in the first month after vortioxetine treatment, clinically significant improvement was observed in the patient's depressive complaints, while a partial reduction in RLS symptoms was observed.

Keywords: Antidepressant; dopamine; restless legs syndrome; vortioxetine.

Publication types

  • Case Reports